Log In
BCIQ
Print this Print this
 

SND12

  Manage Alerts
Collapse Summary General Information
Company SyneuRx International Taiwan Corp.
DescriptionUndisclosed combination therapy
Molecular Target
Mechanism of Action 
Therapeutic Modality 
Latest Stage of DevelopmentPhase II/III
Standard IndicationSchizophrenia
Indication DetailsTreat refractory schizophrenia as combination therapy
Regulatory Designation U.S. - Breakthrough Therapy (Treat refractory schizophrenia as combination therapy);
U.S. - Orphan Drug (Treat refractory schizophrenia as combination therapy)
Partner

 Product Details
 Archive Items are loading loading
Collapse Summary Deals Information
 Deals Details
Get a free BioCentury trial today